1. Son M, Yun JW. Cancer mortality projections in Korea up to 2032. J Korean Med Sci 2016;31:892–901. PMID:
27247498.
2. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444–1450. PMID:
2202842.
3. Påhlman LA, Hohenberger WM, Matzel K, Sugihara K, Quirke P, Glimelius B. Should the benefit of adjuvant chemotherapy in colon cancer be re-evaluated? J Clin Oncol 2016;34:1297–1299. PMID:
26903571.
4. Carriquiry LA, Piñeyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 1999;42:921–929. PMID:
10411440.
5. Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997;185:55–59. PMID:
9208961.
6. Chu DZ, Erickson CA, Russell MP, Thompson C, Lang NP, Broadwater RJ, et al. Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Serum levels before and after resection and before recurrence. Arch Surg 1991;126:314–316. PMID:
1998473.
7. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408–3419. PMID:
15199089.
8. Lin JK, Lin CC, Yang SH, Wang HS, Jiang JK, Lan YT, et al. Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer. Int J Colorectal Dis 2011;26:1135–1141. PMID:
21538056.
9. Park YA, Lee KY, Kim NK, Baik SH, Sohn SK, Cho CW. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol 2006;13:645–650. PMID:
16538413.
10. Jung TD, Yoo JH, Lee MJ, Park HK, Shin JH, An MS, et al. Prognostic significance of the decreased rate of perioperative serum carcinoembryonic antigen level in the patients with colon cancer after a curative resection. Ann Coloproctol 2013;29:115–122. PMID:
23862129.
11. Lee WS, Baek JH, Kim KK, Park YH. The prognostic significant of percentage drop in serum CEA post curative resection for colon cancer. Surg Oncol 2012;21:45–51. PMID:
21094039.
12. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–1474. PMID:
20180029.
13. Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012;30:3353–3360. PMID:
22915656.
14. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A;. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010;21(Suppl 5): v70–v77. PMID:
20555107.
15. Moertel CG, O'Fallon JR, Go VL, O'Connell MJ, Thynne GS. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986;58:603–610. PMID:
3731019.
16. Rapellino M, Piantino P, Pecchio F, Ruffini E, Cavallo A, Scappaticci E, et al. Disappearance curves of tumor markers after radical surgery. Int J Biol Markers 1994;9:33–37. PMID:
8051433.
17. Holyoke ED, Chu TM, Murphy GP. CEA as a monitor of gastrointestinal malignancy. Cancer 1975;35:830–836. PMID:
1111949.
18. Hotta T, Takifuji K, Yokoyama S, Matsuda K, Oku Y, Nasu T, et al. Impact of the post/preoperative serum CEA ratio on the survival of patients with rectal cancer. Surg Today 2014;44:2106–2115. PMID:
24504847.
19. Sun Z, Wang F, Zhou Q, Yang S, Sun X, Wang G, et al. Pre-operative to post-operative serum carcinoembryonic antigen ratio is a prognostic indicator in colorectal cancer. Oncotarget 2017;8:54672–54682. PMID:
28903373.
20. Erden G, Barazi AO, Tezcan G, Yildirimkaya MM. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals. Scand J Clin Lab Invest 2008;68:212–218. PMID:
17926198.
21. Sölétormos G, Schiøler V, Nielsen D, Skovsgaard T, Dombernowsky P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 1993;39:2077–2083. PMID:
8403393.
22. Tuxen MK, Sölétormos G, Petersen PH, Schioler V, Dombernowsky P. Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol 1999;74:12–22. PMID:
10385546.